List of Excipients in Branded Drug METHENAMINE HIPPURATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
County Line Pharmaceuticals LLC	METHENAMINE HIPPURATE	methenamine hippurate	43199-020	MAGNESIUM STEARATE
County Line Pharmaceuticals LLC	METHENAMINE HIPPURATE	methenamine hippurate	43199-020	POVIDONE
County Line Pharmaceuticals LLC	METHENAMINE HIPPURATE	methenamine hippurate	43199-020	SACCHARIN SODIUM

Generic Drugs Containing METHENAMINE HIPPURATE

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	methenamine hippurate	0115-1754	FD&C YELLOW NO. 6
Amneal Pharmaceuticals of New York LLC	methenamine hippurate	0115-1754	MAGNESIUM STEARATE
Amneal Pharmaceuticals of New York LLC	methenamine hippurate	0115-1754	POVIDONE

What are the Most Frequently-Used Excipients in METHENAMINE HIPPURATE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
2	CROSPOVIDONE
4	FD&C YELLOW NO. 6

Methenamine Hippurate Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Methenamine hippurate is an established urinary anti-infective with limited patent protection, no biosimilar exposure, and a low-complexity immediate-release tablet market. The main commercial opportunities are reliable generic supply, lower-cost tablet manufacturing, differentiated liquid or patient-friendly dosage forms, and excipient systems that improve moisture stability and dose uniformity. The principal technical constraint is maintaining methenamine stability while preserving urinary conversion to formaldehyde in acidic urine.

What is the FDA-approved use of methenamine hippurate?

Methenamine hippurate is an oral urinary antiseptic used for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. The product is not intended to treat active systemic infections, renal parenchymal infections, or infections caused by organisms resistant to formaldehyde activity.

The reference product is HIPREX, supplied as 1-gram tablets. The labeled adult dose is generally 1 gram twice daily. Pediatric dosing is weight- and age-dependent under the product labeling.[1]

Methenamine is converted to formaldehyde in acidic urine. Hippuric acid contributes to urinary acidification but is not the principal antimicrobial component. The pharmacological mechanism makes urinary pH, renal function, and concomitant medicines important to product positioning.

Attribute	Methenamine hippurate
Active ingredient	Methenamine hippurate
Common strength	1 g tablet
Therapeutic class	Urinary antiseptic
Main use	Suppression or prophylaxis of recurrent urinary tract infection
Dosage form	Immediate-release oral tablet
Key activation condition	Acidic urine
Primary technical risk	Moisture and acid-base compatibility
Biosimilar exposure	None
Reference brand	HIPREX
Regulatory pathway for copies	Abbreviated New Drug Application, generally
Patent dependence	Low for the legacy active ingredient and standard tablet

What excipients are used in methenamine hippurate tablets?

Commercial methenamine hippurate tablets generally use conventional immediate-release excipients for powder flow, compression, disintegration, lubrication, and mechanical strength. The exact composition varies by manufacturer and should be confirmed from the current product label and regulatory filing.

Common excipient categories include:

Excipient function	Suitable examples	Formulation purpose
Diluent and compression aid	Pregelatinized starch, microcrystalline cellulose, lactose where compatible	Tablet mass and hardness
Binder	Povidone, pregelatinized starch	Granule or tablet strength
Disintegrant	Crospovidone, sodium starch glycolate, croscarmellose sodium	Rapid tablet breakup
Glidant	Colloidal silicon dioxide	Powder flow and weight control
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and tooling protection
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Handling, identification, swallowability
Moisture barrier	Opadry-type coating systems, high-barrier blister packaging	Protection against humidity

The formulation should avoid excipients that materially alter urinary pH after administration. The tablet itself does not need to acidify urine to the extent that a therapeutic claim can be made, but excessive alkalinizing or buffering components could work against methenamine conversion after absorption.

What is the preferred excipient platform?

A conventional direct-compression or dry-granulation platform is commercially attractive. It minimizes processing steps, reduces water exposure, and supports low-cost manufacturing.

A practical starting formula would use:

• A low-moisture diluent or pregelatinized starch system
• Crospovidone or sodium starch glycolate as the primary disintegrant
• Povidone only if additional binding is required
• Colloidal silicon dioxide for flow
• Magnesium stearate at the lowest level that meets ejection requirements
• A moisture-protective film coat where stability data support the added cost

Wet granulation is less attractive unless powder flow, content uniformity, or compressibility requires it. Water-based granulation introduces a process variable for a compound whose long-term stability should be protected from unnecessary moisture.

How does methenamine hippurate chemistry affect excipient selection?

Methenamine is a formaldehyde-generating compound that decomposes more readily under acidic conditions and in the presence of water. The formulation objective is to maintain chemical stability in the tablet while allowing conversion after the active ingredient reaches acidic urine.

Moisture control

Moisture protection is the most important excipient and packaging issue. Development should evaluate:

• Water activity
• Equilibrium moisture content
• Tablet hardness after storage
• Methenamine assay
• Related substances, including formaldehyde-related degradation products
• Dissolution after accelerated and long-term storage
• Packaging ingress through bottles, closures, and blisters

High-moisture excipients should be controlled or excluded unless they provide a clear manufacturing advantage. Lactose, starches, cellulose derivatives, and some superdisintegrants can carry different moisture loads depending on grade and storage conditions.

A low-moisture direct-compression grade can reduce variability. If starch is used, incoming moisture specifications and supplier change controls should be tight.

Acid-base compatibility

The formulation should be screened for local microenvironmental pH. Strongly acidic excipients may increase solid-state degradation, while alkaline excipients may create a formulation environment that affects stability or dissolution. The correct target is not simply a low tablet pH. It is a stable solid dosage form that releases methenamine without compromising the urinary mechanism.

Compatibility studies should include binary blends and the final formulation with:

• Differential scanning calorimetry
• Thermogravimetric analysis
• Powder X-ray diffraction where relevant
• High-performance liquid chromatography assay and impurities
• Moisture uptake under controlled humidity
• Dissolution across physiologically relevant pH conditions

Lubrication

Magnesium stearate is widely used but can reduce wettability and slow dissolution at excessive concentrations or mixing times. The development program should establish a defined lubrication endpoint rather than treating lubricant addition as a fixed formula percentage.

Sodium stearyl fumarate may be considered where faster wetting, lower hydrophobicity, or reduced sensitivity to over-lubrication is needed. Any substitution requires comparative dissolution and stability work.

Tablet size and patient use

A 1-gram dose produces a relatively large tablet. A high-density formulation can reduce tablet volume, but excessive hardness may impair disintegration. Film coating can improve swallowability and reduce odor or handling concerns without changing the immediate-release profile.

A scored tablet could support dose flexibility, but score performance must be validated. A 1-gram tablet may also be difficult for some older adults, the principal population for recurrent urinary tract infection prevention.

What formulation patents protect methenamine hippurate?

The core methenamine hippurate molecule and standard immediate-release tablet are legacy technologies. The principal commercial product is not dependent on a recent formulation patent or biologic exclusivity period.

Potentially protectable areas include:

• Low-moisture tablet compositions
• Specific excipient ratios
• Taste-masked liquid or dispersible formulations
• Modified-release products
• Combination products with urinary acidification components
• Unit-dose sachets or orally disintegrating tablets
• Manufacturing processes that reduce degradation
• Stabilized aqueous suspensions
• Patient-specific pediatric dosage forms

Patentability depends on unexpected stability, bioavailability, dissolution, manufacturability, or clinical performance. A simple substitution of one conventional disintegrant for another would face a substantial obviousness risk.

A company pursuing intellectual property should focus on measurable technical advantages, such as:

1. A materially longer shelf life under high humidity.
2. A liquid formulation with demonstrated chemical stability.
3. A smaller tablet with equivalent dissolution and bioequivalence.
4. A pediatric dosage form with validated dose uniformity.
5. A formulation that improves adherence without changing the immediate-release profile.

When does methenamine hippurate lose exclusivity?

Methenamine hippurate has already lost the practical exclusivity associated with the original branded product. The reference product dates to the legacy drug approval era, and generic versions are marketed.

Exclusivity category	Current position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current commercial significance identified
Reference-product patent blocking	No core modern barrier identified
Biosimilar exclusivity	Not applicable
Generic competition	Established
Main regulatory barrier	ANDA quality, bioequivalence, manufacturing, and supply compliance

The FDA Orange Book remains the controlling source for current listed patents and exclusivity. A standard methenamine hippurate tablet does not have the type of active Orange Book patent estate associated with newer specialty drugs.[2]

What is the Orange Book status of methenamine hippurate?

Methenamine hippurate is a small-molecule drug available through the conventional generic pathway. The relevant regulatory issues are product sameness, pharmaceutical equivalence, bioequivalence, quality, and labeling.

For a conventional immediate-release tablet, a generic applicant typically must demonstrate:

• The same active ingredient and strength
• The same dosage form and route
• Pharmaceutical equivalence
• Bioequivalence under the applicable FDA standard
• Compliance with current good manufacturing practice
• Acceptable stability and impurity controls
• Appropriate labeling referencing the listed drug

The product is not a biologic, so biosimilar approval pathways do not apply. A liquid, chewable tablet, orally disintegrating tablet, or modified-release product may require a different regulatory strategy and could face additional clinical or pharmacokinetic requirements.

Are there Paragraph IV challenges or litigation risks?

Paragraph IV risk is limited for the conventional product because the active ingredient and ordinary tablet technology are mature. A Paragraph IV certification could still arise if a manufacturer targets a listed formulation or method-of-use patent, but a substantial current patent dispute is not a defining feature of the methenamine hippurate market.

Risk area	Assessment
Core active ingredient patent	Low
Standard tablet formulation patent	Low
Method-of-use patent exposure	Low to moderate, depending on the claim
Patent litigation	Limited for the legacy product
Settlement risk	Low for the standard generic tablet
Regulatory litigation	More likely to concern approval, labeling, or manufacturing than patent validity
Trade-secret risk	Possible for proprietary excipient ratios or process controls

No biosimilar litigation exists because methenamine hippurate is a chemically synthesized small molecule. A formulation entrant could create a new patent dispute if it claims a differentiated dosage form, but that dispute would concern the new formulation rather than the basic drug.

What commercial opportunities exist for methenamine hippurate?

The largest opportunity is a dependable, low-cost generic product. The active ingredient is inexpensive relative to development and manufacturing costs, so commercial performance depends on scale, quality, channel access, and supply reliability.

Opportunity 1: Standard generic tablets

The standard 1-gram tablet has the lowest technical and regulatory risk. Differentiation can come from:

• Lower cost per tablet
• Consistent supply
• Smaller tablet dimensions
• Better bottle or blister packaging
• More reliable score performance
• Improved coating and swallowability
• Contract manufacturing for regional suppliers

The market is likely price-sensitive. A new entrant needs manufacturing efficiency or a supply advantage rather than a premium excipient story alone.

Opportunity 2: Pediatric liquid formulation

A liquid formulation could address patients who cannot swallow a large tablet. The technical difficulty is substantial because methenamine stability in water must be demonstrated over the proposed in-use period.

Development requirements include:

• Aqueous and nonaqueous vehicle screening
• Preservative compatibility
• Container-closure interaction
• Dose uniformity after shaking
• In-use stability
• Microbial limits
• Palatability
• Syringe or cup dosing accuracy

A liquid product could support a higher price than a commodity tablet if it solves a recognized administration problem. The formulation should avoid unnecessary alkalinizing buffers and should control formaldehyde-related degradation.

Opportunity 3: Smaller or orally disintegrating tablets

A smaller tablet or orally disintegrating tablet could improve adherence among older patients. The principal formulation issues are high drug loading, taste, mouthfeel, rapid disintegration, and moisture protection.

Taste masking is particularly important because methenamine-containing products can have an unpleasant taste. Polymer coatings, ion-exchange systems, flavoring, and multiparticulate technologies are possible, but each increases development cost and may create a new bioequivalence burden.

Opportunity 4: Unit-dose packaging

Unit-dose blister packaging can improve pharmacy handling, nursing-home distribution, and moisture control. It may be commercially useful even without a new dosage form.

The business case is strongest where:

• Products are dispensed through institutional channels.
• Humidity exposure causes bottle stability concerns.
• Adherence packaging is reimbursed or valued by the buyer.
• The manufacturer wants a differentiated package without changing the active formulation.

Opportunity 5: Private-label and contract supply

Methenamine hippurate is suitable for private-label arrangements because the product has a known clinical use, mature manufacturing process, and limited need for promotional investment. Manufacturers can compete through:

• ANDA ownership
• Authorized private-label distribution
• Hospital and long-term-care contracts
• Pharmacy benefit coverage
• Regional wholesaler supply
• Dual-site manufacturing

The main commercial risk is low absolute market value. A single product disruption can create shortages, but shortage-driven pricing is not a stable long-term strategy.

How strong is the patent estate for methenamine hippurate?

The patent estate is weak for the conventional product and potentially moderate for differentiated formulations.

IP layer	Strength	Commercial implication
Methenamine hippurate active ingredient	Weak or expired	Open generic competition
1-gram immediate-release tablet	Weak	Limited exclusivity
Conventional excipient selection	Weak unless unexpected results exist	Difficult to defend broadly
High-barrier packaging	Moderate as a combination of product and package claims	Useful for differentiation
Pediatric liquid	Moderate if stability and dosing advantages are demonstrated	Potential specialty opportunity
Orally disintegrating tablet	Moderate	May support formulation exclusivity
Modified release	Uncertain and technically difficult	Higher development risk
Manufacturing process	Moderate if impurity or stability results are unexpected	Possible trade-secret and patent protection

A strong patent position would require more than a standard excipient list. The applicant should generate comparative data against the reference product and conventional generic formulas. Relevant evidence includes impurity reduction, shelf-life extension, dissolution performance, tablet-size reduction, and in-use stability.

What manufacturing and IP barriers affect market entry?

The manufacturing process is not intrinsically complex, but quality risk is concentrated in stability and process control.

Key barriers include:

• Active pharmaceutical ingredient supply qualification
• Control of moisture during blending and compression
• Tablet weight and content uniformity at high drug loading
• Lubrication control
• Dissolution after storage
• Packaging moisture ingress
• Impurity method validation
• Supplier change management
• Demonstration of commercial-scale reproducibility

For an established tablet, the manufacturing barrier is lower than the commercial barrier. New entrants may obtain approval but struggle to reach acceptable margins if they lack purchasing scale or distribution access.

A formulation company can create more defensible value by combining:

• A moisture-controlled tablet
• A validated high-barrier package
• A differentiated patient presentation
• A reliable supply agreement
• A targeted institutional or long-term-care channel

How does methenamine hippurate compare with antibiotic prophylaxis?

Methenamine hippurate is positioned as a non-antibiotic urinary antiseptic for recurrent urinary tract infection prevention. It does not carry the same antibacterial resistance-selection profile as conventional antibiotic prophylaxis, although clinical decision-making depends on patient characteristics, urine pH, renal function, infection history, and guideline recommendations.

Its commercial advantages are:

• Long clinical history
• Oral administration
• Generic pricing
• No antibiotic-class resistance mechanism
• Potential use in recurrent infection suppression

Its limitations are:

• Dependence on acidic urine
• Unsuitability for some renal or hepatic patients
• Large tablet size
• Limited use for active upper-tract infection
• Need for adherence to twice-daily dosing in the labeled adult regimen

The product competes less on novel pharmacology than on tolerability, availability, price, and physician acceptance.

What FDA and market risks should investors monitor?

Regulatory risk is concentrated in product quality rather than patent expiry. The most relevant indicators are:

1. FDA approval or withdrawal of ANDAs.
2. Product recalls involving assay, dissolution, contamination, or labeling.
3. Drug shortage listings and manufacturing interruptions.
4. Changes in the reference product label.
5. New formulations requiring clinical bridging.
6. Supplier concentration for the active ingredient.
7. Contract manufacturing inspection outcomes.
8. Market consolidation among generic suppliers.

Revenue exposure is difficult to isolate because manufacturers commonly group methenamine hippurate with broader generic portfolios. Public filings generally do not report the product as a separate material revenue line. The product is more likely to be strategically important as a portfolio filler, institutional contract item, or shortage-sensitive generic than as a major branded revenue driver.

Key Takeaways

• Methenamine hippurate is a mature, generic small-molecule urinary antiseptic with no biosimilar risk.
• The standard 1-gram immediate-release tablet has low patent and development risk but limited pricing power.
• Moisture control, impurity management, and excipient compatibility are the central formulation issues.
• Direct compression or dry granulation is generally more attractive than wet granulation because it limits water exposure.
• A conventional excipient substitution is unlikely to create strong intellectual property without unexpected technical results.
• Pediatric liquids, orally disintegrating tablets, smaller tablets, and unit-dose packaging offer the clearest formulation opportunities.
• The best commercial strategy combines low-cost manufacturing with reliable supply and differentiated packaging or administration.
• Patent and litigation risk is low for the standard tablet; regulatory, quality, and supply risks are more relevant.
• A defensible formulation patent would need comparative evidence showing improved stability, dissolution, dose delivery, or patient usability.

FAQs

Can methenamine hippurate be formulated as a suspension?

Yes, but an aqueous suspension would require rigorous chemical and microbiological stability testing. A nonaqueous or dry-powder-for-reconstitution approach may offer better stability, but it would increase manufacturing and labeling complexity.

Which excipient is best for methenamine hippurate tablet disintegration?

Crospovidone, sodium starch glycolate, and croscarmellose sodium are reasonable candidates. The optimal choice depends on tablet hardness, moisture exposure, dissolution, and compatibility data rather than on excipient identity alone.

Does methenamine hippurate require an acidifying excipient?

Not necessarily. Methenamine activity depends on acidic urine after absorption, but adding an acidifying excipient to the tablet does not automatically improve clinical performance and may create solid-state stability problems.

Is an extended-release methenamine hippurate product commercially attractive?

It could provide dosing convenience, but the product would face formulation, pharmacokinetic, and regulatory challenges. The commercial value would need to justify a higher development cost in a low-priced generic market.

Can a new excipient combination obtain patent protection for methenamine hippurate?

Yes, if the combination produces a non-obvious and measurable benefit, such as improved shelf life, reduced degradation, smaller tablet size, or better dissolution. A routine combination of known diluents, binders, disintegrants, and lubricants would have limited patent strength.

References

1. U.S. Food and Drug Administration. (n.d.). HIPREX (methenamine hippurate) tablet: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Methenamine hippurate drug products and labeling information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

4. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

5. European Association of Urology. (2024). EAU guidelines on urological infections. https://uroweb.org/guidelines/urological-infections